San MediTech Joins the Joslin Institute for Technology Translation (JITT) As a Founding Member
BOSTON – (June 11, 2015) – Joslin Diabetes Center announced today that San MediTech, located in Beijing, China, has joined the Joslin Institute for Technology Translation (JITT) as a Founding Member.
Howard Hao, President and CEO, San Meditech, Co. Ltd., and John L. Brooks III, President and CEO, Joslin Diabetes Center, celebrate San Meditech joining as a Founding Member of JITT.
JITT, an innovation group at Joslin, is focused on leveraging the potential of technology with the introduction of clinical solutions, decision support tools and the advancement of digital health to improve the lives of people with diabetes.
San MediTech is dedicated to improving the quality of life of diabetics throughout Asia by developing high quality, low cost continuous glucose monitoring (CGM) devices. San MediTech was founded in 2003 in Zhejiang, and has been active as the only Chinese CGM company since 2006. Most recently, San MediTech revealed their 4th generation CGM, which integrates a miniature sensor, a Bluetooth enabled transmitter, and a cloud support platform for remote diabetes management.
“As the global diabetes epidemic and the digital revolution have grown in parallel, future care will become inseparable from technology,” said William C. Hsu, M.D., Vice President of International Programs at Joslin Diabetes Center and Assistant Professor at Harvard Medical School. “Patient-centric technology can ease the burden of living with the complex challenges of diabetes by helping patients to better understand the impact of diet, exercise and medication on their health. We are delighted that San Meditech is joining JITT in this effort.
Harry Mitchell, Executive Director of JITT, echoed Dr. Hsu’s sentiments on the intersection between technology and diabetes care, which will continue to create new opportunities to improve diabetes care.
“The use of technology and digital health is critical for improving patient care for people with diabetes – here and around the world,” said Mitchell. “We look forward to working with San Meditech and providing clinical guidance to advance their technology.”
San MediTech is putting forward an initiative to support the Chinese government’s “One Belt, One Road” plan by providing resources to clinics and small companies across Asia, with a special focus on Gestational Diabetes Mellitus. This initiative will help pregnant mothers to handle glucose fluctuations during pregnancy via remote monitoring through San MediTech’s CGM data platform.
“The integration of smartphones, medical devices, and big-data analysis presents an excellent opportunity to better empower diabetics to manage their own disease,” said Howard Hao, CEO of San MediTech. “Partnering with JITT will allow diabetics across Asia to benefit from the best practices and technical expertise of the exceptional team at JITT.”
Joslin Diabetes Center and the Joslin Institute for Technology Translation do not promote or endorse any product. Revenue and fees received by JITT will be invested in digital health to improve patient care.